Tasty, I came to the same conclusion about a month or two ago. I would prefer a year or two of GIA, but cannot ignore how this is playing out. Talk about slow walking. I too believe that it's about the patent trial. I have mentioned before that James Murphy at the shareholders meeting was told by a board member that 2nd quarter 2020 was when things would happen. This was mentioned at a time when we thought we could be approved in August or September eliminating any concerns about making 2020 formularies with a CVD indication. The board member statement made no sense in that context unless you had a different plan in place involving a 3rd party. The patents are the key as they were already expected to go to court 1st quarter 2020. It's the most logical answer to how this has played out. Assuming the case ends with an AMRN win, it would be a great time to go big.